All Digestive disorders articles
-
NewsImmune profiling could help tailor treatment for primary biliary cholangitis
A new review of primary biliary cholangitis reveals how interactions between bile duct epithelial cells and immune populations sustain chronic inflammation, and explores whether mapping individual disease mechanisms could guide more targeted therapies.
-
NewsMLY2 and MLY8 compounds show promise as ulcerative colitis treatment candidates
Two experimental compounds derived from a phase II metabolite have demonstrated improved anti-inflammatory activity in preclinical models of ulcerative colitis.
-
NewsResearchers solve 30-year mystery of key inflammatory enzyme gene
A gene responsible for producing a critical enzyme in inflammatory signalling has been identified after more than 30 years, with findings suggesting the pathway acts as both an immune alarm and a cellular shield with implications for cancer, IBD and asthma.
-
NewsBacterial enzyme found to weaken gut protective hormone signal
A bacterial enzyme produced by Bacteroides vulgatus has been shown to inactivate the intestinal hormone GLP-2, disrupting gut barrier function and aggravating colitis in a preclinical model — with a natural product inhibitor identified as a potential intervention.
-
NewsPancreas organoids reveal CFTR dysfunction as chronic pancreatitis drug target
Researchers at the Salk Institute have developed a patient-derived organoid platform that identifies distinct biological subtypes of chronic pancreatitis and highlights CFTR as a potential therapeutic target, raising prospects for more personalised treatments.
-
NewsTranexamic acid cuts post-hepatectomy liver failure risk threefold
An international multi-centre study has found that tranexamic acid, a widely available and inexpensive haemostatic agent, could reduce the risk of post-hepatectomy liver failure threefold, offering a potential new preventive strategy for one of liver surgery’s most feared complications.
-
NewsFerroptosis emerges as strategy against treatment-resistant digestive cancers
Researchers are investigating ferroptosis, an iron-dependent cell death pathway, as a potential approach to overcome treatment resistance in digestive cancers.
-
News3D-printed system doubles growth speed of transplantable gut organoids
A novel 3D-printed confined culture system has enabled researchers to generate larger, more advanced human gastrointestinal organoids in half the time of traditional methods, producing transplantation-ready tissues with self-organised enteric neural networks within 14 days.
-
NewsMetal microrobots deliver drugs and biopsies before dissolving
Swallowable metal microrobots that transform shape to deliver drugs and collect tissue samples before safely dissolving could replace invasive endoscopy procedures.
-
NewsRepurposed cancer drugs target root cause of Crohn’s Disease
Researchers at the University of Houston have identified epithelial stress signalling as a key driver of Crohn’s disease and demonstrated that two FDA-approved cancer drugs can interrupt the pathological cycle of cell death and inflammation.
-
NewsNew AI genomics platform targets kidney and cardiorenal disease
Seattle-based biotech company, Variant Bio, have launched Inference, an AI-powered genomics platform designed to accelerate drug discovery and identify genetically supported targets.
-
NewsBlocking PAF receptor could offer new liver cirrhosis treatment
Spanish researchers have discovered a key inflammatory mechanism that could lead to new innovative treatments to reduce liver damage and improve vascular function in cirrhosis.
-
NewsAI-powered CKD drug ISM4808 licensed for kidney disease therapy
Insilico Medicine has partnered with TaiGen Biotechnology to exclusively license its AI-designed PHD inhibitor, ISM4808, for the treatment of CKD-related anaemia in Greater China.
-
NewsFibulin-5 linked to early detection of liver fibrosis
Researchers in Japan have identified a promising blood-based marker that could enable faster, simpler and more accurate detection of liver fibrosis.
-
NewsKidney fibrosis linked to overactive Hippo signalling pathway
Scientists have used human stem cell–derived kidney organoids to uncover how abnormal Hippo signalling drives scarring in nephronophthisis, a rare genetic kidney disease.
-
NewsTargeting p300 may boost immunotherapy in kidney cancer
Researchers have discovered how renal medullary carcinoma cells evade immunotherapy by mimicking immune cells, driving rapid tumour progression.
-
ArticleMapping the genome in 3D to reveal new drug targets
Find out how a three-dimensional view of the genome is giving scientists a clearer picture of disease biology and revealing new opportunities for targeted therapies.
-
NewsLab-grown liver offers new platform to test fibrosis drugs
Japanese scientists have developed a lab-grown liver organoid that mimics human liver regeneration, offering a new platform to study fibrosis and test therapies.
-
NewsPulmonary fibrosis: new drug slows and reverses lung scarring
Researchers have identified a key cellular mechanism that drives pulmonary fibrosis and successfully blocked it in mice, reducing lung scarring.
-
NewsStem cell liver model reproduces rare immune drug reactions
A new human liver organoid platform could help predict which drugs trigger dangerous immune reactions in susceptible patients.